Neuren pays the price for sellside froth
The Australian group has found a partner for its lead asset at last, so why is the stock down?
Where is the IPO class of 2014-15 now?
A golden age for biotech flotations yielded some spectacular blow-ups, but also saw several groups reward investors with premium-priced takeovers.
Biotech gets creative about the pay cheque
Amid a backlash over the high prices of advanced therapies, biotech companies are coming up with new payment models.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.